BACKGROUND: venous thromboembolism (VTE) is a well-known complication in adults with acute lymphoblastic leukemia (ALL), especially in patients treated with asparaginase (ASNase)-including regiments. However, VTE risk in adult Philadelphia-positive ALL (Ph+ve ALL) patients treated with non-hyperCVAD chemotherapy is unclear. In this study, we examined VTE incidence in adult Ph+ve ALL patients treated with imatinib plus a pediatric-inspired asparaginase (ASNase)-free regimen modified from the Dana Farber Cancer Institute (DFCI) ALL protocol. METHODS: a single centre retrospective review of Ph+ve ALL patients treated at Princess Margaret Cancer Center (PMCC) from 2008-2019 with imatinib plus modified DFCI protocol was conducted. RESULTS: of the 123 patients included, 30 (24.3%) had at least 1 radiology confirmed VTE event from diagnosis to the end of maintenance therapy. 86.7% (26/30) of the VTE events occurred during active treatment. Of all VTE events, the majority (53.3%) were DVT and/or PE while another significant portion were catheter-related (40.0%). Major bleeding was observed in 1 patient on VTE treatment with low molecular weight heparin (LMWH). CONCLUSION: a high VTE incidence (24.3%) was observed in adults Ph+ve ALL patients treated with imatinib plus an ASNase-free modified DFCI pediatric ALL protocol, suggesting prophylactic anticoagulation should be considered for all adult Ph+ve ALL patients including those treated with ASNase-free regimens.
BACKGROUND:venous thromboembolism (VTE) is a well-known complication in adults with acute lymphoblastic leukemia (ALL), especially in patients treated with asparaginase (ASNase)-including regiments. However, VTE risk in adult Philadelphia-positive ALL (Ph+ve ALL) patients treated with non-hyperCVAD chemotherapy is unclear. In this study, we examined VTE incidence in adult Ph+ve ALL patients treated with imatinib plus a pediatric-inspired asparaginase (ASNase)-free regimen modified from the Dana Farber Cancer Institute (DFCI) ALL protocol. METHODS: a single centre retrospective review of Ph+ve ALL patients treated at Princess Margaret Cancer Center (PMCC) from 2008-2019 with imatinib plus modified DFCI protocol was conducted. RESULTS: of the 123 patients included, 30 (24.3%) had at least 1 radiology confirmed VTE event from diagnosis to the end of maintenance therapy. 86.7% (26/30) of the VTE events occurred during active treatment. Of all VTE events, the majority (53.3%) were DVT and/or PE while another significant portion were catheter-related (40.0%). Major bleeding was observed in 1 patient on VTE treatment with low molecular weight heparin (LMWH). CONCLUSION: a high VTE incidence (24.3%) was observed in adults Ph+ve ALL patients treated with imatinib plus an ASNase-free modified DFCI pediatric ALL protocol, suggesting prophylactic anticoagulation should be considered for all adult Ph+ve ALL patients including those treated with ASNase-free regimens.
Authors: Robert D McBane; Waldemar E Wysokinski; Jennifer G Le-Rademacher; Tyler Zemla; Aneel Ashrani; Alfonso Tafur; Usha Perepu; Daniel Anderson; Krishna Gundabolu; Charles Kuzma; Juliana Perez Botero; Roberto A Leon Ferre; Stanislav Henkin; Charles J Lenz; Damon E Houghton; Prakash Vishnu; Charles L Loprinzi Journal: J Thromb Haemost Date: 2019-11-28 Impact factor: 5.824
Authors: Rachael F Grace; Daniel J DeAngelo; Kristen E Stevenson; Donna Neuberg; Stephen E Sallan; Yasser R Abou Mourad; Julie Bergeron; Matthew D Seftel; Caroline Kokulis; Jean M Connors Journal: J Thromb Thrombolysis Date: 2018-02 Impact factor: 2.300
Authors: V De Stefano; F Sorà; E Rossi; P Chiusolo; L Laurenti; L Fianchi; G Zini; L Pagano; S Sica; G Leone Journal: J Thromb Haemost Date: 2005-09 Impact factor: 5.824
Authors: Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman Journal: Blood Date: 2016-04-11 Impact factor: 22.113
Authors: Giancarlo Agnelli; Cecilia Becattini; Guy Meyer; Andres Muñoz; Menno V Huisman; Jean M Connors; Alexander Cohen; Rupert Bauersachs; Benjamin Brenner; Adam Torbicki; Maria R Sueiro; Catherine Lambert; Gualberto Gussoni; Mauro Campanini; Andrea Fontanella; Giorgio Vescovo; Melina Verso Journal: N Engl J Med Date: 2020-03-29 Impact factor: 91.245
Authors: D J DeAngelo; K E Stevenson; S E Dahlberg; L B Silverman; S Couban; J G Supko; P C Amrein; K K Ballen; M D Seftel; A R Turner; B Leber; K Howson-Jan; K Kelly; S Cohen; J H Matthews; L Savoie; M Wadleigh; L A Sirulnik; I Galinsky; D S Neuberg; S E Sallan; R M Stone Journal: Leukemia Date: 2014-07-31 Impact factor: 11.528